People

  1. Schaff
    Schaff
  2. Lipitz Snyderman
    Lipitz Snyderman
  3. Ho
    Ho
  4. Sumer
    Sumer
  5. Pritchett
    Pritchett
  6. Gany
    Gany
  7. Cohen
    Cohen
  8. Poirier
    Poirier
  9. Koche
    Koche
  10. Sanchez-Rivera
    Sanchez-Rivera
  11. Lu
    Lu
  12. Arnold
    Arnold
  13. Featherstone
    Featherstone
  14. Zeuren
    Zeuren
  15. Houston
    Houston

Recent Works

  1. Patient-centered outcomes in ARIEL3, a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
    Meeting Abstract

    Bedel, D. J.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  2. Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
    Value in Health (2019)

    Fulltext@MSK | Save
  3. Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk
    Meeting Abstract

    Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R.
    Value in Health (2019)

    Fulltext@MSK | Save